Akèy › Kansè tete negatif triple › Arizona
Etid klinik pou Kansè tete negatif triple nan Arizona
18 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
PRE-ISPY Phase I/II Oncology Platform Program
- Mayo Clinic Comprehensive Cancer Center, Phoenix
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT05868226A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Banner MD Anderson Cancer Center ( Site 0066), Gilbert
- Mayo Clinic Cancer Center ( Site 0034), Phoenix
- University of Arizona Cancer Center ( Site 0035), Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Ironwood Cancer & Research Centers-Research ( Site 0054), Chandler
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Ironwood Cancer & Research Centers ( Site 0036), Chandler
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06841354A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- HonorHealth Research Institute, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07705334Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Palo Verde Hematology Oncology, Glendale
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- HonorHealth, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 3, 2026 · NCT06635980Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR HonorHealth, Phoenix
- USOR Arizona Oncology Associates, Tucson
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Phoenix
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Mayo Clinic - Scottsdale, Scottsdale
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- HonorHealth Research and Innovation Institute, Scottsdale
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 29, 2025 · NCT06249048A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Banner MD Anderson Cancer Center, Gilbert
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT06682793A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Arizona Oncology Associates, Tucson
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 19, 2025 · NCT06568692CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Arizona Oncology, Tucson
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Jan 7, 2025 · NCT06230185Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- HonorHealth Research Institute, Scottsdale
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 15, 2024 · NCT04787042Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- HonorHealth Research Institute, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 8, 2024 · NCT04282044Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.